Salesforce Stock Has Surged as AI and Anthropic Bets Pay Off, But Technical Risks Remain
Salesforce stock has surged to its highest level in months as its AI and Anthropic bets paid off, but its technical risks remain
Stocks · News reference
Nasdaq Surges 300 Points; Amazon Shares Jump Following Upbeat Earnings
US stocks rise, Nasdaq up 300 points. Dow up 0.36%, Nasdaq up 1.31%, S&P 500 up 0.65%. Amazon shares jump 14% after posting strong Q2 results.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Gary Black Says Tesla Has Solved Unsupervised Autonomy, but Competition Is the Bigger Threat
Gary Black says Tesla has achieved unsupervised autonomy but warns competition and a stretched valuation could pressure its stock.
Anthropic's $2 Trillion IPO Approaches: The Companies Poised to Benefit
Anthropic, the creator of Claude, the popular AI chatbot, is set to launch its IPO in the coming weeks. Here are the companies to benefit
Michael Dell’s Net Worth Up $110 Billion So Far 2026: Why the Surge May Continue
Michael Dell has added $110 billion this year as his net worth gains momentum amid the ongoing Dell stock surge.
BioAge Labs to Present at Upcoming Investor Conferences
BioAge Labs announced the first participant has been dosed in QUELL-CV, a Phase 2 proof-of-concept trial evaluating BGE-102, an oral NLRP3 inhibitor, in patients with elevated cardiovascular risk and systemic inflammation. Topline data is anticipated in the second half of 2026. The company also announced participation in three upcoming investor conferences in September 2026.
Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight
DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.